Program will be added once finalised.
DAY 1
Thursday, 22 October 2026
8h30
Registration & welcome coffee
9h00
Welcome Address
9h15
Opening Keynotes
- Plenary
Chaired by Ana Antunes - MabDesign and Sandra Morel - GSK
9h15
The HITS Institute: at the crossroads of academia and industry
Bruno Versaevel
Head of the Healthcare Innovation, Technology & Society (HITS) Institute
emlyon HITS Institute - France
9h30
The Pandemic Alliance Munich: Collaborating to Accelerate Innovation in Pandemic Preparedness
Regina Bach
Coordination Lead Pandemic Alliance Munich
BioM Biotech Cluster Development - Germany
9h45
Rethinking Active Immunisation: Prevention, Protection, and Beyond
Jamila Louahed
CDO
Minervax - Denmark
10h15
Track 1: Learning from experience to strengthen pandemic preparedness
- Plenary
Chaired by Sophie Trouillet-Assant - REVIDA and Marta Nunes - VIRESP
10h15
From Genomic Surveillance to Public Health Impact: Bridging Viral Evolution and Clinical Outcomes
Marta Nunes
Director of the Center of Excellence in Respiratory Pathogens
Hospices Civils de Lyon and Université Claude Bernard Lyon 1 - France
10h45
Viral Dynamic Models During COVID-19: Are We Ready for the Next Pandemic?
Jérémie Guedj
Research scientist in biostatistics/pharmacometrics
INSERM - France
11h05
Diagnostic testing in pandemics: what can we do now to prepare for the next pandemic?
Maria Zambon
Head of Respiratory Virology
UK Health Security Agency (UKHSA) - United Kingdom
9h30
Title to be confirmed
Jamila Louahed
Deputy Executive Director
Child Health Research Foundation (CHRF) - Bangladesh
12h00
Lunchbreak - Exhibition Hall
14h00
Track 2: Innovations in human vaccines
- Plenary
Sponsored by Sanofi
Chaired by Daniel Larocque - Sanofi and Sandra Morel - GSK
14h00
Accelerating Vaccine Development Through Controlled Human Infection Models
Meta Roestenberg
Infectious Diseases clinician and professor in Human Models for Vaccine Development
Leiden University Medical Center (LUMC) - Netherlands
14h25
AI/ML-Driven mRNA Vaccine Development: From Design to Clinical Translation
Margaux Hubert
Principal Data Scientist - Computational Immunology
Sanofi - France
14h55
Strategic Partnerships as Key Enablers of Sanofi’s Vaccine Portfolio
Daniel Larocque
Innovation Lead
Sanofi - France
15h15
Q&A session
15h35
Coffe Break - Exhibition Hall
16h15
Track 3: Global Challenges in Animal Infectious Diseases
- Plenary
Chaired by Lionel Cupillard - Boehringer Ingelheim and Sotiris Missailidis - Pasteur Institute
16h15
Development of a Leptospira Australis experimental challenge model using a virulent canine field isolate and evaluation of the efficacy of two multivalent L4 vaccines against mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions
Lionel Cupillard
Executive Director Infectious Diseases
Boehringer Ingelheim - France
16h35
CCHFV in Europe: Where Do We Stand? A Veterinary Public Health Perspective
Vincent Legros
Associate professor
VetAgro Sup - France
16h55
Track 4: One Health Approach to Tackling Infectious Diseases
- Plenary
Chaired by Lionel Cupillard - Boehringer Ingelheim and Sotiris Missailidis - Pasteur Institute
16h55
Advancing Vaccine Development for Leishmaniasis
Thouraya Boussoffara
Head of the team “Immunobiology of Infections”
Institut Pasteur de Tunis - Tunisia
17h15
Deciphering Host–Vector–Pathogen Interactions to Combat Infectious Diseases
Valérie Choumet
Researcher
Institut Pasteur - France
17h35
Nforce – One unified RNA platform enabling One Health - How one construct-agnostic sa/mRNA platform designs and makes personalized cancer vaccines, animal vaccines and human vaccines
Ashiqul Haque
CSO
Quantoom Biosciences - Belgium
17h55
Q&A session
18h15